Sunil Mehra, MD
Pulmonary Disease · Brooklyn, NYNPI 1740252295
Payments from drug & device makers
Across 738 payments — averaging $525.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$224K
- GSK$141K
- Sunovion Pharmaceuticals Inc.$11K
- Boehringer Ingelheim$4K
- Amgen$1K
- Sanofi-aventis U.S. LLC$867
- plus $7K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 325 | $224,237 |
| GSK | 201 | $140,762 |
| Sunovion Pharmaceuticals Inc. | 37 | $10,502 |
| Boehringer Ingelheim | 55 | $3,879 |
| Amgen(2 entities) | 10 | $1,043 |
| Sanofi-aventis U.S. LLC | 7 | $867 |
| Abbott | 5 | $609 |
| Viiv Healthcare Company | 1 | $600 |
| Insmed, Inc. | 12 | $573 |
| Intuity Medical Inc | 6 | $555 |
| Boston Scientific | 4 | $466 |
| Dexcom, Inc. | 4 | $437 |
| Johnson & Johnson | 6 | $417 |
| Novo Nordisk | 4 | $372 |
| Regeneron Healthcare Solutions, Inc. | 7 | $348 |
| Actelion Pharmaceuticals US, Inc. | 13 | $323 |
| Olympus America Inc. | 2 | $269 |
| Mannkind Corporation | 2 | $203 |
| Viatris Specialty LLC | 6 | $145 |
| Mylan Specialty L.p. | 2 | $136 |
| Cequr Corporation | 1 | $131 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Pfizer | 1 | $125 |
| Valeritas, Inc. | 1 | $125 |
| Bayer | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $119 |
| Novartis | 4 | $73 |
| Paratek Pharmaceuticals, Inc. | 3 | $67 |
| Merck | 3 | $62 |
| Advanced Respiratory, Inc | 3 | $59 |
| RGH Enterprises LLC | 1 | $35 |
| Verona Pharma, Inc. | 1 | $34 |
| Inogen, Inc. | 2 | $34 |
| Electromed, Inc. | 1 | $32 |
| Genentech USA, Inc. | 1 | $21 |
| Sanofi | 1 | $20 |
| Circassia Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
How this compares
$388,097 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$547K
- Aaliya BurzaBrooklyn$334K
- Xiaojun YanBrooklyn$249K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.